Table 2 The clinical, laboratory and radiological features of RSV-associated bronchiolitis in the training group
|  | training group (n = 227) | mild bronchiolitis (n = 137) | severe bronchiolitis (n = 90) | P |
|---|---|---|---|---|
Age, monthsb | 5(2–10) | 6(3–12) | 3(1.8–7.0) | 0.000 |
Sex, male/female | 146/81 | 84/53 | 62/28 | 0.244 |
weight at admission, kgb | 7.7(6.2–9.6) | 8.4(7.1–9.8) | 6.5(5.2–8.6) | 0.000 |
Region, rural/urban | 79/148 | 39/98 | 40/50 | 0.013 |
preterm birth, n(%) | 27(11.9%) | 11(8%) | 16(17.8%) | 0.026 |
cesarean section, n(%) | 121(53.3%) | 65(47.4%) | 56(62.2%) | 0.029 |
history of birth asphyxia, n(%) | 5(2.2%) | 1(0.7%) | 4(4.4%) | 0.062 |
birth weight, kgb | 3.3(3.0–3.6) | 3.3(3.0–3.5) | 3.3(2.9–3.6) | 0.672 |
non-breastfeeding, n(%) | 124(54.6%) | 76(55.5%) | 48(53.5%) | 0.751 |
underlying diseases, n(%) | 12(5.3%) | 4(2.9%) | 8(8.9%) | 0.049 |
history of wheezing, n(%) | 16(7.0%) | 11(8%) | 5(5.6%) | 0.476 |
history of eczema, n(%) | 106(46.7%) | 67(48.9%) | 39(43.3%) | 0.410 |
Fever, n(%) | 128(56.4%) | 89(65%) | 39(43.3%) | 0.001 |
Length of cough, daysb | 4(3–6) | 4(3–6) | 4(3–6) | 0.687 |
Length of wheezing, daysb | 1(0–3) | 1(0–3) | 1(0–3) | 0.05 |
Outpatient use of antibiotics, n(%) | 168(74%) | 101(73.7%) | 67(74.4%) | 0.903 |
Outpatient use of glucocorticoids, n(%) | 57(25.1%) | 29(21.2%) | 28(31.1%) | 0.091 |
Breath rateb | 45(40–51) | 40(38–45) | 51(46–56) | 0.000 |
Three concave signs, n(%) | 66(29.1%) | 0(0%) | 66(73.3%) | 0.000 |
Abnormal lung auscultation, n(%) | 224(98.7%) | 135(98.5%) | 89(98.9%) | 0.822 |
Abnormal radiological findings, n(%) | 141(62.1%) | 83(60.6%) | 58(64.4%) | 0.558 |
Length of stay, daysb | 6(5–7) | 5(4–6) | 7(6–8) | 0.000 |
WBC, × 109/La | 8.6 ± 3.3 | 8.6 ± 3.4 | 8.7 ± 3.2 | 0.819 |
N%a | 33.1 ± 15.6 | 32.1 ± 15.4 | 34.8 ± 15.7 | 0.206 |
L%a | 56.1 ± 15.1 | 57.6 ± 14.6 | 53.9 ± 15.7 | 0.073 |
E%b | 0.0(0.0–2.0) | 0.0(0.0–2.0) | 0.0(0.0–2.0) | 0.607 |
Hb, g/Lb | 114(105–121) | 115(107–123) | 111(104–119.3) | 0.024 |
CRP, mg/Lb | 2.5(2.5–3.0) | 2.5(2.5–2.8) | 2.5(2.5–3.7) | 0.614 |
PCT, ng/mlb | 0.07(0.05–0.10) | 0.07(0.06–0.10) | 0.08(0.05–0.11) | 0.661 |
IL-6, pg/mlb | 7.7(4.4–12.4) | 7.7(3.8–14.4) | 7.6(4.7–13.2) | 0.712 |
La, mol/Lb | 3.2(2.6–3.9) | 3.2(2.6–4.0) | 3.2(2.7–3.9) | 0.741 |
AST, U/Lb | 43.0(34.0–58) | 45(35–56.5) | 41(33.8–60.3) | 0.403 |
ALT, U/Lb | 22.0(16–32) | 21.0(15–31.5) | 22(16.8–33.3) | 0.200 |
CK, U/Lb | 104(78–146) | 97(67–139) | 110.5(87.5–157.8) | 0.011 |
CKMB, U/Lb | 12(7.0–23) | 11(7.0–20.5) | 16.5(9.0–30.0) | 0.022 |
LDH, U/Lb | 392(337–482) | 380(334.5–447) | 415.0(338.8–538.5) | 0.042 |
IgE, IU/Lb | 11.5(3.3–38.7) | 14.8(4.2–47.7) | 8.7(2.8–25.3) | 0.027 |